Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659458 · ClinicalTrials.gov registry record
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
A clinical trial of Lung Cancer, Non-Small Cell and EGFR Exon 19 Deletion Mutation, sponsored by Our Lady of the Lake Hospital.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06659458: Recruiting study of Lung Cancer, Non-Small Cell and EGFR Exon 19 Deletion Mutation, sponsored by Our Lady of the Lake Hospital.
NCT06659458 is a study of Lung Cancer, Non-Small Cell and EGFR Exon 19 Deletion Mutation that is actively recruiting participants, run by Our Lady of the Lake Hospital. The registered enrollment target is 20 participants, below the 454-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06659458, a study of Lung Cancer, Non-Small Cell and EGFR Exon 19 Deletion Mutation, is actively recruiting participants, sponsored by Our Lady of the Lake Hospital.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Primary Outcome
Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.
Conditions Studied
Interventions
- OTHER blood draw
- OTHER Gene sequencing
Study Locations (1)
Louisiana
- Our Lady of the Lake Regional Medical Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2025-12-31 |
What NCT06659458 shows while recruiting
NCT06659458 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 454-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 2 interventions - of which blood draw is the first listed.
NCT06659458 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06659458 about?
NCT06659458 is a clinical study titled "Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients". EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect bloo...
What is the current status of trial NCT06659458?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-01-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06659458 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell, EGFR Exon 19 Deletion Mutation.
What interventions are being tested in trial NCT06659458?
The interventions under investigation include: blood draw (OTHER), Gene sequencing (OTHER).
Who is sponsoring clinical trial NCT06659458?
This trial is sponsored by Our Lady of the Lake Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659458 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06659458's enrollment target sits among peer trials
20 16th of 16 higher than 1 of 16 other Lung Cancer, Non-Small Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RECRUITING · Phase 1
-
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RECRUITING
-
A Multicenter Cancer Biospecimen Collection Study
RECRUITING
-
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI